Delayed sleep phase syndrome linked to irregular menstrual cycles, premenstrual symptoms in women

Jun 10, 2008

Women with delayed sleep phase syndrome are more likely to report irregular menstrual cycles and premenstrual symptoms, according to a research abstract that will be presented on Tuesday at SLEEP 2008, the 22nd Annual Meeting of the Associated Professional Sleep Societies (APSS).

The study, authored by Kari Sveum, of Northwestern University in Chicago, Ill., focused on 13 females with delayed sleep phase syndrome and 13 healthy controls. The subjects responded to a questionnaire regarding their reproductive health, including irregularity of their cycle and premenstrual symptoms, either in the past or present.

According to the results, twice as many subjects with delayed sleep phase syndrome reported an irregular menstrual cycle compared to controls. For those not using birth control, three times as many subjects with delayed sleep phase syndrome reported irregular menstruation, compared to controls. Pre-menstrual problems, such as cramps and mood swings, were reported by 69 percent of those with delayed sleep phase syndrome, compared to 16.67 percent of controls.

“While the data is preliminary, these results suggest that women with delayed sleep phase syndrome may be at increased risk for menstrual irregularity associated with circadian misalignment,” said Sveum. “Further investigation with a larger group of subjects using prospective diary data would be useful to further establish the effects of circadian disruption on reproductive cycles in women with delayed sleep phase syndrome.”

Sleep plays a vital role in promoting a woman’s health and well being. Getting the required amount of sleep is likely to enhance a woman’s overall quality of life. Yet, women face many potential barriers – such as life events, depression, illness, and medication use – that can disrupt and disturb her sleep.

The hormonal and physical changes that occur during and after menopause can also affect a woman’s sleep. Sleep disturbances are more common, and sleep quality can decline. Insomnia related to menopause often occurs.

Obstructive sleep apnea (OSA) is much more common in postmenopausal women. This increase may be due in part to menopause-related weight gain. But it also appears to be hormone-related. Estrogen seems to help protect women against OSA.

It is recommended that women get between seven and eight hours of nightly sleep.

Source: American Academy of Sleep Medicine

Explore further: Face transplants change lives, identity

add to favorites email to friend print save as pdf

Related Stories

Endeavour soars on 2nd-to-last space shuttle trip

May 16, 2011

Endeavour blasted off on NASA's next-to-last shuttle flight, thundering through clouds into orbit Monday morning as the mission commander's wounded wife, Gabrielle Giffords, watched along with an exhilarated ...

UK: New guidelines to ease sleepless nights

Sep 02, 2010

Insomnia and other sleep disorders are very common, yet are not generally well understood by doctors and other health care professionals. Now the British Association for Psychopharmacology (BAP) has released up-to-the-minute ...

LED glasses step into the light

Aug 02, 2010

(PhysOrg.com) -- Light therapy glasses -- spectacles that use inbuilt light emitting diodes (LEDs) to assist in resetting the body's natural clock -- are a step closer to commercial availability with the award ...

Recommended for you

Face transplants change lives, identity

49 minutes ago

Patients are prepared to take significant risks in order to be considered for a face transplant, says Dr David Koppel, director of the largest craniofacial unit in the UK and Honorary Clinical Associate Professor ...

British Lords hold ten-hour debate on assisted dying

Jul 19, 2014

Members of Britain's unelected House of Lords spent almost ten hours on Friday discussing whether to legalise assisted dying, in an often emotional debate putting the question back on the agenda, if not on the statute books.

AbbVie, Shire agree on $55B combination

Jul 18, 2014

The drugmaker AbbVie has reached a deal worth roughly $55 billion to combine with British counterpart Shire and become the latest U.S. company to seek an overseas haven from tax rates back home.

User comments : 0